AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS

AngioDynamics (NASDAQ:ANGO) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.16, Zacks reports. The firm had revenue of $72.00 million for the quarter, compared to analyst estimates of $70.30 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm’s revenue for the quarter was down 4.3% on a year-over-year basis. AngioDynamics updated its FY 2025 guidance to -0.340–0.310 EPS and its FY25 guidance to ($0.34)-($0.31) EPS.

AngioDynamics Trading Up 12.4 %

AngioDynamics stock opened at $10.86 on Thursday. The company’s 50-day moving average is $10.28 and its two-hundred day moving average is $8.85. The company has a market cap of $439.46 million, a PE ratio of -1.93 and a beta of 0.56. AngioDynamics has a 1 year low of $5.47 and a 1 year high of $13.50.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price target on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 10th.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.40% of the stock is owned by corporate insiders.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.